A Phase 1 Open-Label Study of Genetically Engineered Oncolytic HSV-1 (C5252) Expressing IL-12 and Anti-PD-1 Antibody in Patients With Recurrent or Progressive Glioblastoma
Latest Information Update: 13 Oct 2022
At a glance
- Drugs MVR C5252 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; First in man
- Sponsors Immvira Pharma
- 09 Oct 2022 Planned primary completion date changed from 30 Apr 2023 to 15 Mar 2023.
- 09 Oct 2022 Status changed from recruiting to not yet recruiting.
- 17 Feb 2022 Planned initiation date changed from 31 Dec 2021 to 28 Feb 2022.